Risperidone and parkinson's disease
S. Factor,E. Molho,J. Friedman
DOI: https://doi.org/10.1002/mds.1258
IF: 9.698
Movement Disorders
Abstract:Risperidone and Parkinson’s Disease We read with interest the article by Mohr and colleagues on risperidone treatment of psychosis in Parkinson’s disease (PD). We wish to address the notion that risperidone may be an alternative therapy for psychosis in PD. This drug has been available in the United States since 1994. There have been several studies reporting results of its use in this situation, most of which are open-label. To summarize, 82 patients were treated with risperidone and 23 (33%) suffered worsening of motor features of PD, most to a fairly significant level. There has been one double-blind comparison with clozapine which, despite the small patient numbers (nine patients), demonstrated that risperidone worsened PD symptoms while clozapine improved them. These findings and the other available alternatives, quetiapine and clozapine, would indicate that risperidone should not be utilized to treat PD patients. There are several issues discussed in this article which we would like to address. First, risperidone should not be considered “atypical.” Its receptor binding profile is more typical than atypical. Knable and colleagues examined D2 receptor occupancy of risperidone and haloperidol using IBZM SPECT and found no difference. Both drugs produced a 60–90% occupancy at standard doses with a substantial portion of patients in both groups experiencing drug-induced parkinsonism. A similar result was reported by Kapur and associates in a raclopride positron emission tomography study. They found a similar D2 receptor occupancy between risperidone and typical neuroleptics, both of which were much higher than that seen with clozapine. Finally, its ability to cause extrapyramidal side effects appears to be similar to more typical agents. Rosebush and Mazurek compared the side effects of risperidone and haloperidol in neuroleptic-naïve psychotic patients. This was a prospective analysis of 350 neuroleptic-naïve patients admitted to an acute care psychiatric facility (34 treated with risperidone, mean dose, 3.2 mg/day; and 212 treated with haloperidol, mean dose, 3.7 mg/day). Extrapyramidal symptoms were measured using the Barnes Akathisia Scale (BAS), a modified version of the motor portion of the UPDRS, the AIMS scale and acute dystonia was assessed as present or absent. Incidence of all three groups of symptoms were comparable for both drugs, with parkinsonism occurring in over 50%, indicating that risperidone behaves more like a typical than an atypical agent and causes parkinsonism at lower doses than reported in schizophrenia trials. It also causes increased prolactin levels in a dose-related fashion. In addition, there have been a number of reports of cases of tardive dyskinesia induced by risperidone in patients not previously exposed to standard agents. Second, the authors indicated that patients had to be withdrawn from “current antipsychotic medication.” What antipsychotics were used? If typical agents were utilized prior to risperidone one might not expect a change in parkinsonism. That change may have already occurred. Third, the most important issue regarding the use of atypical antipsychotics in PD relates to changes in motor function. The authors contradict themselves in several areas regarding this point. They indicate that UPDRS total and subscores showed no significant changes during treatment and thus indicated that “risperidone treatment did not coincide with a deterioration in parkinsonian symptoms.” However, 10 patients were noted to have hypokinesia as an adverse effect and seven had increased drooling; a problem not typically associated with this drug (as it is with clozapine). These findings would appear to reflect a worsening of parkinsonism. How can this occur without worsening of the UPDRS? Based on the data given it would seem safe to say that, as we do not know if the hypokinesia and drooling occurred in the same patients, at least 10 (59%) had a worsening of their parkinsonism. Furthermore, they describe one patient in the safety section with “hypokinesia, anxiety, impaired concentration and abnormal gait” and indicate this is “possibly” related to treatment. This description appears to be a case of worsening parkinsonism very likely due to the drug. Finally, despite this information they note that the “study was not powered sufficiently to definitively answer the issue of motor worsening” but also say that risperidone is “relatively well-tolerated in patients with PD.” Fourth, it should also be noted that the authors suggest that motor worsening in past studies was related to the use of a higher dose than theirs, but, in fact, some of the studies in PD reported similar doses. Standard neuroleptics can improve psychosis in PD, but the key issue is their negative impact on the motor symptoms. It would appear that risperidone, which behaves like, and for all intents and purposes is, a typical agent, worsens symptoms of parkinsonism in a substantial portion of patients and the results of this article and others support that interpretation. Considering the currently available choices of antipsychotics for PD, risperidone should not be considered a favorable alternative.